Elan lives on. No, former CEO Kelly Martin isn’t swooping back in his infamous corporate jet. Elan was a high-profile Irish-American biotech that created the multiple sclerosis treatment natalizumab (Tysabri), developed the promising but unsuccessful Alzheimer’s treatment bapineuzumab, and built a billion-dollar drug-delivery business.
But a long boil of shareholder discontent over management practices (the jet was but one sticking point) sealed its fate, and Elan was ultimately broken up.
